Cargando…

Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who fail to respond to anti‐HER2 treatments have poor prognoses. Most trastuzumab‐resistant breast cancer cell lines available from biobanks feature either phosphoinositide‐3‐kinase, catalytic, alpha (PI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Wei‐Pang, Huang, Wei‐Lun, Liao, Wei‐An, Huang, Wan‐Ling, Liu, You‐Yu, Su, Wu‐Chou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982635/ https://www.ncbi.nlm.nih.gov/pubmed/33665980 http://dx.doi.org/10.1002/cam4.3824

Ejemplares similares

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Macro-CK and CK-BB Contributing to Sham CK-MB Elevation
por: Wada, Yuki, et al.
Publicado: (2017)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
por: Yong, Kwon J, et al.
Publicado: (2013)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
por: Zhang, Anli, et al.
Publicado: (2010)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study
por: Zheng, Qi, et al.
Publicado: (2021)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
por: Bouwer, Nathalie I., et al.
Publicado: (2022)

Corrigendum: Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study
por: Zheng, Qi, et al.
Publicado: (2022)

Fangjihuangqi Decoction inhibits MDA‐MB‐231 cell invasion in vitro and decreases tumor growth and metastasis in triple‐negative breast cancer xenografts tumor zebrafish model
por: Guo, Yubo, et al.
Publicado: (2020)

Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK–MB Immunoassays
por: Zwirner, Johann, et al.
Publicado: (2021)

Ultrasound Targeted Apoptosis Imaging in Monitoring Early Tumor Response of Trastuzumab in a Murine Tumor Xenograft Model of Her-2–Positive Breast Cancer(1)()
por: Wei, Xi, et al.
Publicado: (2014)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
por: Chung, Yuan-Chiang, et al.
Publicado: (2015)

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2017)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Evaluation of creatine kinase (CK)-MB to total CK ratio as a diagnostic biomarker for primary tumors and metastasis screening
por: Li, Yan, et al.
Publicado: (2023)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line
por: Korch, Christopher, et al.
Publicado: (2017)

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
por: Bruni, Sofia, et al.
Publicado: (2023)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Case report: One child with an autism spectrum disorder who had chronically elevated serum levels of CK and CK-MB
por: Rong, Ping, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer
por: Polychronopoulou, Efstathia, et al.
Publicado: (2022)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study
por: Wu, Shengwei, et al.
Publicado: (2021)

High coronary calcium score and post-procedural CK-MB are noninvasive predictors of coronary stent restenosis
por: Lee, Jae-Beom, et al.
Publicado: (2017)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

High-sensitive cardiac troponins and CK-MB concentrations in patients undergoing cardiac surgery
por: Mey, N De, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_co9qrrqr4t3rrrqb4q2bbp0o3t